Prehabilitation in Pancreatic Surgery

Pancreatic Cancer Clinical Trial

— PIPS  

Official title:

Multimodal Prehabilitation in Localized Pancreatic Cancer Patients Undergoing Surgery: a Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06069297
• Other study ID #: GR-2021-12374985
• Status: Recruiting
• Phase: N/A
• Start date: July 14, 2023
• Est. completion date: July 13, 2026

Study information

• Verified date: September 2023
• Source: IRCCS San Raffaele
• Contact: Nicolò Pecorelli, MD
• Phone: +390226432111
• Email: pecorelli.nicolo[@]hsr.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In patients with pancreatic cancer, older age, multiple comorbidities, frailty, malnutrition and poor functional status are common, especially in individuals receiving neoadjuvant chemotherapy. These characteristics represent potentially modifiable risk factors for poor postoperative outcomes.

The goal of this clinical randomized controlled trial is to evaluate the extent to which a four-week multimodal prehabilitation program impacts on postoperative morbidity, functional and nutritional status and health-related quality of life in patients with localized pancreatic or periampullary cancer scheduled for curative surgery.

In addition, the impact of prehabilitation on circulating sarcopenia and cancer cachexia biomarkers in PDAC patients will be explored.

Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation.

Description:

BACKGROUND:

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with 5-year survival around 10%. The combination of surgical resection and chemotherapy represents the most efficacious therapy to improve prognosis for localized PDAC. Patients with pancreatic cancer are generally older adults in whom frailty, sarcopenia and/or malnutrition are common. These features have all been associated with poor postoperative complications and reduced survival. Therefore, the preoperative period and the time window after the end of chemotherapy constitute a unique opportunity to condition modifiable risk factors, improve functional capacity and address deficiencies in physiologic reserves, which might otherwise preclude surgery or significantly impede recovery.

Prehabilitation is defined as the process of enhancing patients' functional capacity to enable them to withstand a stressful event. Multimodal prehabilitation, which defines a program including physical, nutritional, and psychological interventions, has shown the most promising results in gastrointestinal cancer surgery. However, no high-quality evidence is currently available for PDAC patients.

STUDY OBJECTIVES:

Primary Aim: to evaluate if a 4-week multimodal structured prehabilitation program including physical exercise, nutritional and psychological interventions will result in a clinically significant increase in functional capacity, nutritional status and patient-reported health-related quality of life before surgery when compared to a usual care control group, and evaluate the extent to which multimodal prehabilitation impacts on postoperative morbidity and patient recovery compared to usual care.

Secondary Aim: to analyze whether multimodal prehabilitation may impact on the concentration and activity of a panel of specific circulating molecules involved in cancer cachexia and skeletal muscle wasting, chronic inflammation.

STUDY DESIGN:

A randomized controlled trial will be performed in PDAC and periampullary cancer patients with indication to upfront pancreatic resection or pancreatic resection after completion of neoadjuvant chemotherapy.

Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation. All patients will receive the same intraoperative and postoperative care based on an established enhanced recovery pathway.

Inclusion and exclusion criteria as stated in the eligibility section will be assessed and patients consented to participate in the study if they fulfill inclusion criteria.

RANDOMIZATION AND BLINDING:

The trial is designed as a randomized, controlled, assessor-blind trial. Participants will be randomly assigned to either multimodal prehabilitation or no prehabilitation group with a 1:1 allocation using permuted blocks of random sizes. Randomization will be stratified by neoadjuvant chemotherapy and tumor location (periampullary or pancreatic head-neck cancer versus pancreatic body-tail cancer). Allocation concealment will be ensured as the randomization code will not be released until the patient has been recruited into the trial, which takes place after all baseline measurements have been completed and informed consent has been signed.

PREOPERATIVE ASSESSMENT:

All patients will be evaluated at baseline (T0) by:

• Patient medical history including comorbidities, presence of signs or symptoms, and frailty assessment using Fried's criteria.

• Physical performance tests including functional walking capacity (six-minute walk test), timed up and go test, gait speed assessment and handgrip strength test.

• Assessment of nutritional status by nutrition history, measurement of anthropometric parameters, completion of nutritional screening questionnaires (MNA, PG-SGA), and standard biochemical markers of malnutrition and inflammation including albumin, prealbumin, total lymphocyte count, and C-reactive protein.

• Body composition measurements assessed using two methods:

• multi-frequency bioelectrical impedance analysis (BIA) providing data on extracellular and intracellular water as % of total body water, fat mass (FM) as % of body weight, skeletal muscle mass (SK) as % of fat-free mass (FFM) and phase angle (PA°), intramuscular fat mass (IMAT), basal metabolic rate (BMR) energy expenditure and hypotalamic- pituitary- adrenal axis index (HPA);

• CT scan image analysis (using preoperative cancer staging and restaging chest and abdomen CT scans) performing automated imaging segmentation using Data Analysis Facilitation Suite (DAFS) by Voronoi Health Analytics, Inc. (https://www.voronoihealthanalytics.com/).

• Overall activity of the autonomic nervous system and heart rate variability through photoplethysmography (PPG) stress flow test. This exam allows the study and direct monitoring of all functions of the autonomic nervous system and the related process of biofeedback.

• Patient reported outcome questionnaires to measure health related quality of life and patient engagement. The following questionnaires will be administered

• Patient reported outcome measurement information system (PROMIS)29+2, a validated questionnaire designed to measure self-reported physical, mental and social health and wellbeing.

• Duke activity status index (DASI), a brief questionnaire designed to assess physical function by answering whether they are able to perform 12 listed activities of various intensity (i.e., ambulation, household tasks and leisure activities).

• EORTC QLQ C30, a generic core questionnaire that measures health-related quality of life in patients with any cancer.

• EORTC QLQ PAN-26, the pancreatic cancer module that supplements the EORTC QLQ-C30.

• - Medically unexplained symptoms (MUS) questionnaire investigates the presence of vague symptoms to describe a cluster of manifestations such us chronic fatigue, sleep or appetite disorders, irritable bowel or constipation, tone or mood disorders, non-specific pain syndromes which are sometimes underestimated.

• Patient activation measures (PAM)-13, a 13-item questionnaire measuring patients' self-reported knowledge, motivation, and skills for self-management.

• Hospital Anxiety and Depression Scale (HADS) questionnaire to measure anxiety and depression.

• Blood sample analysis of circulating cytokines, chemokines, interferons, colony stimulating factors, main hormones involved in metabolic homeostasis and cancer cachexia.

Four weeks after baseline assessment, on the day before surgery (T1), all patients will repeat all evaluations previously performed at T0.

STUDY INTERVENTION Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation. Patients in the control group will be treated according to usual standard of care and will be given informative material regarding healthy lifestyle and how to best prepare for surgery.

The intervention will consist of a multimodal prehabilitation, a 4-week long preoperative intervention including exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline as described in the arms and intervention section.

VISITS AND FOLLOW-UP:

Throughout patient hospital stay, postoperative outcomes including complications, will be recorded. After discharge, patients will be followed-up as routine care by phone calls from a nurse navigator.

At 30 days (T2), 60 (T3) and 90 days (T4) after surgery, patient recovery will be re-evaluated during scheduled outpatient visits. Patients will be assessed for:

• Functional capacity by the 6MWT and other physical performance tests including TUG, gait speed assessment and handgrip strength test.

• Nutritional status by measurement of anthropometric parameters including body weight (kg), height (cm), and body mass index (kg/m2)

• Body composition by multi-frequency bioelectrical impedance vector analysis (BIVA)

• Health related quality of life through patient reported outcome questionnaires

STATISTICAL METHODS:

The analysis will be conducted on intention to treat basis. Continuous data will be presented as medians (interquartile range) or means (standard deviation); categorical data as absolute values and percentages. Dichotomous data will be compared by two tailed chi-square test or Fisher's exact test. Continuous measurements will be compared between groups using the Mann-Whitney U test or T-Student test for normally distributed data.

Baseline characteristics of the two groups will be reported in order to confirm the adequacy of the randomization process.

CCI will be described as the mean plus the standard deviation (SD) or median plus interquartile range (IQR), depending on its distribution. To analyze the difference in terms of CCI between groups t-student Test will be adopted in case of normal distribution, otherwise Mann-Whitney U test will be used.

6MWT as a functional capacity measure is a continuous variable. This data will be described as means, plus SD, at each time point. To accommodate the repeat measurements for individuals, a generalized linear mixed model will be used to compare results from both arms.

Pre-planned subgroup analysis in patients with higher risk features at enrollment (e.g., malnourished, sarcopenic obese, low physical function, frail) will also be performed to evaluate the effectiveness of prehabilitation in this population. Statistical analysis will be performed using STATA® version 16 software.

SAMPLE SIZE:

The size of the sample was calculated on the basis of the primary aim of the study: the reduction of postoperative complications as determined with the CCI score at 90 days after surgery. In our preliminary data on PDAC surgical population, the mean (SD) CCI is 21.0 (SD 16), and the target reduction is 30%. An alpha of 0.05 and power of 0.80 (two-sided test) was used. Expecting a dropout rate of 10%, 113 patients are needed in each arm for an overall sample of 226 patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 226
• Est. completion date: July 13, 2026
• Est. primary completion date: July 13, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Indication for curative resection for pancreatic or periampullary cancer

• Signed Informed consent

Exclusion Criteria:

• Metastatic or unresectable disease found preoperatively

• Comorbidities contraindicating prehabilitation regimen (exercise and nutritional intervention) such as orthopedic, cognitive disabilities, chronic renal failure (dialysis or creatinine >250 mmol)

• ASA score 4-5

• Pregnancy

• Illiteracy (inability to read and understand Italian language)

Related Conditions & MeSH terms

• Frailty
• Frailty Syndrome
• Malnutrition
• Pancreatic Cancer
• Pancreatic Neoplasms
• Periampullary Cancer
• Perioperative/Postoperative Complications
• Postoperative Complications

Intervention

Other:
• Multimodal Prehabilitation
Preoperative multimodal intervention including exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline. A personalized intervention program will be prescribed based on specific physical, nutritional and psychological conditions recognized during the multimodal assessment. Patients will follow a two to three-day per week training for 4 weeks. Exercise modalities will be adapted to personal preference and patient conditions. Based on dietary habits, medical conditions and nutritional status, a certified nutritionist will provide a comprehensive diet management program. A food-based intervention with a balanced macronutrient composition coupled with oral nutritional supplements will be prescribed to achieve the estimated daily energy and protein requirements. Participants will be instructed by psychology-trained personnel on how to reduce anxiety.

Locations

Country	Name	City	State
Italy	San Raffaele Hospital	Milan	Lombardia

Sponsors (2)

Lead Sponsor	Collaborator
IRCCS San Raffaele	Ministry of Health, Italy

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Lambert JE, Hayes LD, Keegan TJ, Subar DA, Gaffney CJ. The Impact of Prehabilitation on Patient Outcomes in Hepatobiliary, Colorectal, and Upper Gastrointestinal Cancer Surgery: A PRISMA-Accordant Meta-analysis. Ann Surg. 2021 Jul 1;274(1):70-77. doi: 10.1097/SLA.0000000000004527. — View Citation

Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0. — View Citation

Pecorelli N, Guarneri G, Vallorani A, Limongi C, Licinio AW, Di Salvo F, Tamburrino D, Partelli S, Crippa S, Falconi M. Validation of the PROMIS-29 Questionnaire as a Measure of Recovery after Pancreatic Surgery. Ann Surg. 2023 Jul 19. doi: 10.1097/SLA.0000000000006020. Online ahead of print. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comprehensive Complication Index (CCI)	Postoperative complications occurring during the index admission or in a subsequent readmission, when related to surgery, will be recorded up to 90 days after surgery and graded by severity using the Dindo-Clavien classification and the Comprehensive Complication index (CCI).; The Dindo-Clavien system grades complications according to the therapy needed for treatment: Grade I, are complications that require bedside management; Grade II, are complications that require pharmacologic treatment; Grade III, are complications that require surgical or radiologic intervention and; Grade IV, are complications that require intensive care treatment. Dindo-Clavien Grade III or above are considered severe postoperative complications.; The CCI, derived from the Dindo-Clavien system, is a validated metric summarizing the complete spectrum of complications that occurred and their severity in a single score ranging from 0 to 100.	90 days after surgery
Primary	Functional capacity	Functional capacity will be measured by the 6-minute walking test and compared between groups on the day before surgery, at 30-60-90 days after surgery.	One day before surgery; 30 days after surgery; 60 days after surgery; 90 days after surgery
Primary	Pro-inflammatory cytokines	Circulating levels of tumor necrosis factor alpha (TNF-a), interleukin 1 (IL-1), interleukin 6 (IL-6), interferon gamma (IFN-?), and macrophage inflammatory protein a (MIP-1a) will be assessed by luminex immunoassays and compared between groups at baseline and one day before surgery.	One day before surgery
Primary	Cancer cachexia related factors	Enzyme-linked immunosorbent assay (ELISA) will be used to measure the serum levels of the following cachexia-related factors: Activin A, carnosine dipeptidase-1 and zinc-a2-glycoprotein. The circulating levels will be compared between groups at baseline and one day before surgery.	One day before surgery
Secondary	Time to patient functional recovery (TFR)	TFR will be measured by subtracting the date of surgery from the date when participants achieve standardized criteria (tolerance of oral intake, recovery of lower gastrointestinal function, adequate pain control on oral analgesia, ability to mobilize and self-care and no evidence of untreated medical problems)	90 days after surgery
Secondary	Lenght of stay (LOS)	LOS will be measured by subtracting the date of surgery from the date of discharge	90 days after surgery
Secondary	Bioimpedance analysis (BIA) derived body composition	Extracellular and intracellular water as % of total body water, fat mass (FM) as % of body weight, skeletal muscle mass (SK) as % of fat-free mass (FFM), phase angle (PA°) and intramuscular fat mass (IMAT) will be assessed using bioimpedance analysis and compared between groups at baseline, on the day before surgery, at 30, 60, 90 days after surgery.	One day before surgery; 30 days after surgery; 60 days after surgery; 90 days after surgery
Secondary	Computed tomography derived body composition	Skeletal muscle area (cm2), visceral fat area (cm2) and intra-muscular fat infiltration will be measured at the level of the third lumbar vertebra using preoperative CT scan imaging and compared between groups at baseline and on the day before surgery.	One day before surgery.
Secondary	Generic health-related quality of life	Generic health-related quality of life will be measured using the Patient Reported Outcome Measure Information System (PROMIS)-29+2 Profile v2.1 (PROPr), a questionnaire designed to measure self-reported physical, mental and social health and wellbeing. Questions are ranked on a 5-point Likert Scale. Each domain (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities) is scored from 4 to 20. For negative domains (i.e. Depression), lower scores represent better outcomes, higher scores represent worse outcomes. For positive domains (i.e. Physical function), lower scores represent worse outcomes, higher scores represent better outcomes.	One day before surgery; 30 days after surgery; 60 days after surgery; 90 days after surgery
Secondary	Disease-specific health-related quality of life	Disease-specific health-related quality of life will be measured using the EORTC QLQ C30 and PAN-26 questionnaires, which have been validated to assess quality of life in cancer patients.; EORTC QLQ C30 is a generic core questionnaire that measures health-related quality of life in patients with any cancer. It comprises a total of 30 items on 15 quality of life scales. EORTC QLQ PAN-26, is the pancreatic cancer module that supplements the EORTC QLQ-C30. The module comprises 26 questions that share the 4-level ordinal response options with QLQ-C30.	One day before surgery; 30 days after surgery; 60 days after surgery; 90 days after surgery